^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

NODAL (Nodal Growth Differentiation Factor)

i
Other names: NODAL, Nodal Growth Differentiation Factor, Nodal Homolog, Nodal Mouse Homolog, Nodal Homolog (Mouse), HTX5
3ms
MUC1 in Colorectal Carcinoma: Association With Prognosis and Putative Anoikis-Resistant Structures. (PubMed, APMIS)
In nodal metastases, high MUC1 associates with distant metastasis and poor outcomes. Putative AR structures show high MUC1 expression supporting its role in anoikis resistance.
Journal
|
MUC1 (Mucin 1) • NODAL (Nodal Growth Differentiation Factor)
3ms
Rac1 signaling-associated genes are upregulated in nodal metastasis of canine oral mucosal melanoma. (PubMed, Vet Pathol)
Overall, the results of this investigation point to a significant role for Rac1 signaling in the pathogenesis of OMM metastasis to regional lymph nodes. The Rac1 signaling-associated genes highlighted herein are indeed involved in the activation of cellular migration, and one, or more, may represent a future therapeutic target to prevent metastatic dissemination, or treat OMM with distant metastases.
Journal
|
NODAL (Nodal Growth Differentiation Factor)
3ms
Evaluating CD103+ intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer. (PubMed, Oral Oncol)
This study highlights the discordance in CD103+ ITIC and PD-L1 expression between primaries and nodes, favorable results in high CD103+ ITIC abundance HPVOPC in a surgical cohort consistent with outcomes in chemoradiation cohorts, and promising results suggesting that high PD-L1 CPS in HPVOPC also identifies patients with an excellent prognosis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ITGAE (Integrin Subunit Alpha E) • NODAL (Nodal Growth Differentiation Factor)
|
PD-L1 expression
10ms
Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study. (PubMed, Clin Transl Oncol)
Our real-world data demonstrates that a comprehensive approach considering pCR, age, HR status, and nodal involvement is essential for personalized treatment strategies. These factors should be taken into account when deciding whether to escalate or de-escalate treatment, contributing to improved HER2+ BC patient outcomes.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • NODAL (Nodal Growth Differentiation Factor)
|
HER-2 positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
10ms
A comprehensive transcriptome based meta-analysis to unveil the aggression nexus of oral squamous cell carcinoma. (PubMed, Biochem Biophys Rep)
This study represents the first transcriptomic meta-analysis to explore the intersection of lymph node metastasis and OC recurrence, identifying MEIS1 as a potential key contributor. These comprehensive insights into disease trajectories offer potential biomarkers and therapeutic targets for future treatment strategies.
Retrospective data • Journal
|
MEIS1 (Meis Homeobox 1) • MMP1 (Matrix metallopeptidase 1) • NODAL (Nodal Growth Differentiation Factor) • HTRA1 (HtrA Serine Peptidase 1)
12ms
Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers. (PubMed, Breast J)
Therefore, ERCC1 can be used as a predictive marker to stratify patients who will benefit from neoadjuvant therapy. Moreover, we also noted an association between ERCC1 expression and nodal metastasis; however, more large-scale studies are needed to establish its role as a prognostic biomarker in TNBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ERCC1 (Excision repair cross-complementation group 1) • NODAL (Nodal Growth Differentiation Factor)
1year
Smooth Muscle Myosin Heavy Chain Expression in Nodal and Extranodal Follicular Dendritic Cell Sarcoma. (PubMed, Appl Immunohistochem Mol Morphol)
SMMHC was also negative in all 14 examined cases among 5 common differential diagnoses. We demonstrate that the common IHC marker SMMHC has high specificity and similar sensitivity as established FDC markers in nodal and extranodal FDCS, and is useful in the evaluation of common neoplastic mimics.
Journal
|
CLU (Clusterin) • NODAL (Nodal Growth Differentiation Factor) • FCER2 (Fc Fragment Of IgE Receptor II)
1year
Adjuvant Radiation Therapy in Macroscopic Regional Nodal Melanoma. (PubMed, Cancers (Basel))
After the advent of systemic therapies, a trial of the combination targeted therapy of dabrafenib plus trametinib toward BRAF V600-mutant nodal cutaneous melanoma showed that all 35 patients achieved a pathological response...For those tumours that do recur in-field, there are now competing therapies like Talimogene laherparepvec or T-VEC. Generally, ART is now used at the first recurrence. The challenge now is to find which melanomas are truly radiosensitive if ART is to have any future role in this scenario.
Journal • IO biomarker
|
BRAF (B-raf proto-oncogene) • NODAL (Nodal Growth Differentiation Factor)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • Imlygic (talimogene laherparepvec)
over1year
Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL. (PubMed, Hemasphere)
However, we observed a subgroup of patients classified as BN2, both in localized and disseminated TLBCL, suggesting a degree of genetic heterogeneity in the TLBCL genetic profile. TLBCL has a distinctive genetic profile similar to PCNSL, supporting its recognition as a separate entity from DLBCL and might provide information to devise targeted therapeutic approaches.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • ETV6 (ETS Variant Transcription Factor 6) • CD79B (CD79b Molecule) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • EP300 (E1A binding protein p300) • PIM1 (Pim-1 Proto-Oncogene) • NODAL (Nodal Growth Differentiation Factor) • TBL1XR1 (TBL1X Receptor 1)
|
CDKN2A deletion • MYD88 L265P • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • ETV6 mutation
over1year
Higher Nodal expression is often associated with poorer survival in patients diagnosed with melanoma and treated with anti-PD1 therapy. (PubMed, Pathol Oncol Res)
This pilot study is the first proof-of-principle attempt to predict treatment response survival outcome in a small cohort of melanoma patients receiving anti-PD1 immune checkpoint inhibitor therapy - based on their Nodal expression profile. Using advanced multiplex immunohistochemistry-based digital pathology, the major finding of this preliminary study indicates that higher Nodal expression is often associated with poorer overall survival after anti-PD1 therapy, reaching nearly statistical relevance.
Journal • PD(L)-1 Biomarker • IO biomarker
|
NODAL (Nodal Growth Differentiation Factor)
|
NODAL overexpression
over1year
Cytokeratin 8 depicts nodal metastasis in head and neck squamous cell carcinoma. (PubMed, J Oral Maxillofac Pathol)
CK 14 expression was noted in the entire epithelium and at the ITF, strongly in most cases; however, CK 14 did not correlate with the lymph node metastasis and tumour differentiation as well. We found a strong correlation of CK 8 expression with nodal metastasis in HNSCC, and it can be utilised as a reliable prognostic indicator.
Journal
|
NODAL (Nodal Growth Differentiation Factor)
over1year
Screening for oncogenic AF1q expression predicts disease recurrence in gastric cancer patients. (PubMed, Sci Rep)
Testing AF1q provides a possibility of identifying patients with locoregional (and advanced) disease, particularly at risk for disease recurrence. Implementing AF1q into the diagnostic process may facilitate screening, prognosis estimation as well as consideration of preoperative multimodal treatment in patients qualifying for elective upfront surgery.
Journal
|
CD44 (CD44 Molecule) • NODAL (Nodal Growth Differentiation Factor)